Abstract
Tuberculosis (TB) remains to be a leading infectious cause of death Worldwide. Apparently, the current BCG vaccine that has been used for 80 years, has failed to control the TB epidemic. Hunting for improved TB vaccine formulations represents a daunting task to TB research community. Anti-TB host Defense requires T cell-mediated immunity and we are in desperate need of enhanced understanding of how to develop a new generation of TB vaccines that are able to provoke potent and long-lasting protective cell-mediated immunity, different from almost all of the vaccines currently in use. It is of importance to successful TB vaccine development to identify the key cellular and molecular events governing the generation of anti-TB immunity, but unfortunately little has been understood as to why 90percent of infected humans never develop active TB. However, waiting would not help us to win the battle and an ever-intensifying effort is being made to develop various new formulations according to the immunology that we have been learning, in large part, from experimental models. This review article attempts to unite the current understanding of anti-TB immunity with the rational design of anti-TB vaccines. It examines what may have confounded the immunogenicity of current BCG vaccine and the major obstacles to successful development of TB vaccines. It also discusses about antigen presentation, activation of Th1 and Tc1 cells, anti-TB immune effectors and the generation of memory T cells. The vaccine section describes four types of major TB vaccines under development: mycobacterial-, subunit-, plasmid DNA- and viral-based vaccines. A special section is dedicated to the rationale and current design of cytokine-based adjuvant formulations for TB vaccines. We also take this opportunity to introduce our recent development in cytokine transgene adjuvanted BCG vaccination and recombinant Adenoviral-based TB vaccines.
Keywords: Tuberculosis Vaccines, Anti-TB Immunity, TB immunity, BCG VACCINE, Dendritic Cells, MHC Class, Mycobacterial-based Vaccines, Recombinant BCG, Auxotrophic Mutants, Subunit-based Vaccines
Current Pharmaceutical Design
Title: The Hunt for New Tuberculosis Vaccines: Anti-TB Immunity and Rational Design of Vaccines
Volume: 7 Issue: 11
Author(s): Zhou Xing
Affiliation:
Keywords: Tuberculosis Vaccines, Anti-TB Immunity, TB immunity, BCG VACCINE, Dendritic Cells, MHC Class, Mycobacterial-based Vaccines, Recombinant BCG, Auxotrophic Mutants, Subunit-based Vaccines
Abstract: Tuberculosis (TB) remains to be a leading infectious cause of death Worldwide. Apparently, the current BCG vaccine that has been used for 80 years, has failed to control the TB epidemic. Hunting for improved TB vaccine formulations represents a daunting task to TB research community. Anti-TB host Defense requires T cell-mediated immunity and we are in desperate need of enhanced understanding of how to develop a new generation of TB vaccines that are able to provoke potent and long-lasting protective cell-mediated immunity, different from almost all of the vaccines currently in use. It is of importance to successful TB vaccine development to identify the key cellular and molecular events governing the generation of anti-TB immunity, but unfortunately little has been understood as to why 90percent of infected humans never develop active TB. However, waiting would not help us to win the battle and an ever-intensifying effort is being made to develop various new formulations according to the immunology that we have been learning, in large part, from experimental models. This review article attempts to unite the current understanding of anti-TB immunity with the rational design of anti-TB vaccines. It examines what may have confounded the immunogenicity of current BCG vaccine and the major obstacles to successful development of TB vaccines. It also discusses about antigen presentation, activation of Th1 and Tc1 cells, anti-TB immune effectors and the generation of memory T cells. The vaccine section describes four types of major TB vaccines under development: mycobacterial-, subunit-, plasmid DNA- and viral-based vaccines. A special section is dedicated to the rationale and current design of cytokine-based adjuvant formulations for TB vaccines. We also take this opportunity to introduce our recent development in cytokine transgene adjuvanted BCG vaccination and recombinant Adenoviral-based TB vaccines.
Export Options
About this article
Cite this article as:
Xing Zhou, The Hunt for New Tuberculosis Vaccines: Anti-TB Immunity and Rational Design of Vaccines, Current Pharmaceutical Design 2001; 7 (11) . https://dx.doi.org/10.2174/1381612013397636
DOI https://dx.doi.org/10.2174/1381612013397636 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Computer-Aided Discovery in Antimicrobial Research: In Silico Model for Virtual Screening of Potent and Safe Anti-Pseudomonas Agents
Combinatorial Chemistry & High Throughput Screening Advances and New Perspectives in Medicinal Chemistry Engineering and Bioinformatics (from IWBBIO 2015)
Current Topics in Medicinal Chemistry DFT Based QSAR/QSPR Models in the Development of Novel Anti-tuberculosis Drugs Targeting Mycobacterium tuberculosis
Current Pharmaceutical Design Proteomic Profiling of Maternal Serum for Early Risk Analysis of Preterm Birth
Current Proteomics Molecular Mechanisms in Rheumatic Diseases: Rationale for Novel Drug Development – Introduction
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Doxorubicin-Loaded Nanoparticles: New Advances in Breast Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Targeting Tumor Necrosis Factor-α in the Therapy of Psoriasis
Current Drug Targets - Inflammation & Allergy Lymphadenopathy as a Prodrome for Systemic Lupus Erythematous
Current Rheumatology Reviews Mycobacterial DNA Replication as a Target for Antituberculosis Drug Discovery
Current Topics in Medicinal Chemistry Rip2: A Key Molecule that Regulates both Innate and Acquired Immunity
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents A Computational Study of Molecular Interactions and In Vitro Antibacterial Activity of 6-Substituted Quinoline Carboxylic Acid Derivatives as DNA Gyrase Inhibitors
Letters in Drug Design & Discovery Nose-to-Brain Drug Delivery by Nanoparticles in the Treatment of Neurological Disorders
Current Medicinal Chemistry Anti Tumor Necrosis Factor Alpha (TNFα) Therapy in Ankylosing Spondylitis - Asian Perspective
Current Rheumatology Reviews The State of the Art in Anti-Malarial Drug Discovery and Development
Current Topics in Medicinal Chemistry New Pyrroles with Potential Antimycobacterial, Antifungal and Selective COX-2 Inhibiting Activities. Synthetic Methodologies
Current Organic Chemistry The Endoplasmic Reticulum Alpha-Glycosidases as Potential Targets for Virus Control
Current Protein & Peptide Science HIV Drug Resistance Interpreted by Cumulative Versus Last Genotypes in HIV-Infected Patients with Multiple Treatment Failures
Current HIV Research Tumor Markers in Patients with Benign and Malignant Pulmonary Diseases; Competitive Evaluation of ProGRP, NSE and Cyfra 21-1
Recent Patents on Biomarkers Advances in Drug Discovery and Development for Pediatric Tuberculosis
Mini-Reviews in Medicinal Chemistry Cross-Talk Between Mesenchymal Stem/Stromal Cells and Dendritic Cells
Current Stem Cell Research & Therapy